每经AI快讯，9月29日，迪哲医药（688192）公告，公司于2026年7月14日与阿斯利康（AZN）签署《许可协议》，授予阿斯利康（AZN）在全球范围内独家开发、商业化舒沃哲的权利，协议于2026年8月31日正式生效。近期公司已收到阿斯利康（AZN）支付的6亿美元首付款。每日经济新闻版权所有
Source Link每经AI快讯，9月29日，迪哲医药（688192）公告，公司于2026年7月14日与阿斯利康（AZN）签署《许可协议》，授予阿斯利康（AZN）在全球范围内独家开发、商业化舒沃哲的权利，协议于2026年8月31日正式生效。近期公司已收到阿斯利康（AZN）支付的6亿美元首付款。每日经济新闻版权所有
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.